For research use only.
Catalog No.S1878 Synonyms: RS-21592, BW-759
CAS No. 82410-32-0
Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Selleck's Ganciclovir has been cited by 5 publications
1 Customer Review
Effect of ganciclovir on viral DNA accumulation (A,B) and induction of TGF-β1 production after human cytomegalovirus infection in human trabecular meshwork cells (C). Cells were harvested at 5 day post-infection at a high multiplicity of infection (MOI 1) under the treatment with different concentrations of ganciclovir (GAN). Treatment with 10 μmol of ganciclovir significantly decreased the viral DNA accumulation (p < 0.001) (A,B). However, treatment with ganciclovir did not affect the TGF-β production using a TGF-β1 luciferase bioassay. Results are expressed as the mean +/− standard deviation of three different experiments.
Sci Rep, 2017, 7: 43349. Ganciclovir purchased from Selleck.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
|Description||Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.|
Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: (1) a deoxyguanosine kinase induced by CMV-infected cells; (2) guanylate kinase; and (3) phosphoglycerate kinase.  Ganciclovir is sufficient to induce cell death in most bystander cells cocultured with HSV-tk-expressing cells.  Ganciclovir significantly reduces DNA synthesis in the transformed cells, whereas Ganciclovir has little effect on DNA synthesis in the nontransformed cells. Ganciclovir exhibits a concentration-dependent reduction in the rate of elongation into mature DNA.  Ganciclovir induces cell cycle arrests rather than direct chemical effect on HSVtk-transduced B16F10 melanoma cells.  Ganciclovir produces only weak inhibition of DNA synthesis. Ganciclovir-treated cells accumulate in early S-phase and remained there until cell death, suggesting that ganciclovir incorporation in the DNA template is important for cytotoxicity.  Ganciclovir-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. Ganciclovir-provoked DNA instability is likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. 
|In vivo||Antiviral drug ganciclovir (GCV) inhibits the proliferation of microglia in experimental autoimmune encephalomyelitis (EAE). GCV attenuates neuroinflammation and does not significantly restrain the peripheral immune response.|
-  Matthews T, et al. Rev Infect Dis, 1988, 10, S490-494.
-  Hamel W, et al. Cancer Res, 1996, 56(12), 2697-2702.
-  St Clair MH, et al. Antimicrob Agents Chemother, 1987, 31(6), 844-849.
|In vitro||DMSO||27 mg/mL warmed (105.78 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04478474||Not yet recruiting||Drug: Ganciclovir||Cytomegalovirus Infections||New York Medical College|Merck Sharp & Dohme Corp.||September 15 2020||--|
|NCT03698435||Recruiting||Drug: Ganciclovir|Drug: Valganciclovir||Cytomegalovirus Infections||University Medical Center Groningen||May 25 2018||--|
|NCT02606266||Terminated||Drug: Valganciclovir||Congenital Cytomegalovirus (CMV)||Assistance Publique - Hôpitaux de Paris||July 11 2017||Phase 2|Phase 3|
|NCT03088553||Recruiting||Drug: Therapeutic Drug Monitoring||Solid Organ Transplantation||Rennes University Hospital||February 22 2017||--|
|NCT02943057||Recruiting||Drug: 2% guttae ganciclovir||Cytomegalovirus Infections||Singapore National Eye Centre||October 2016||Phase 4|
|NCT02152358||Active not recruiting||Drug: Aciclovir|Drug: Ganciclovir|Drug: Placebo||Viral Pneumonia||Assistance Publique Hopitaux De Marseille||March 2014||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.